These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 2865903)

  • 21. Schizophrenia: D4 receptor elevation. What does it mean?
    Seeman MV
    J Psychiatry Neurosci; 1994 May; 19(3):171-6. PubMed ID: 7913338
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 receptors in substantia nigra in schizophrenia.
    Owen R; Owen F; Poulter M; Crow TJ
    Brain Res; 1984 May; 299(1):152-4. PubMed ID: 6144367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
    Hippius H; Ackenheil M; Müller-Spahn F
    Adv Biochem Psychopharmacol; 1985; 40():9-13. PubMed ID: 2862769
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
    Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D1 and D2 and D3.
    Healy D
    Br J Psychiatry; 1991 Sep; 159():319-24. PubMed ID: 1683592
    [No Abstract]   [Full Text] [Related]  

  • 29. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schizophrenia and dopamine receptors.
    Seeman P
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):999-1009. PubMed ID: 23860356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
    Pickar D; Breier A; Kelsoe J
    Ann N Y Acad Sci; 1988; 537():339-46. PubMed ID: 2904783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.
    Hartman DS; Civelli O
    Ann Med; 1996 Jun; 28(3):211-9. PubMed ID: 8811164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic drugs and the sigma receptor.
    Hoffman DW
    Am J Psychiatry; 1990 Aug; 147(8):1093-4. PubMed ID: 1973876
    [No Abstract]   [Full Text] [Related]  

  • 36. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
    Frecska E; Perényi A; Bagdy G; Révai K
    Psychiatry Res; 1985 Nov; 16(3):221-6. PubMed ID: 2868474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical assessment of dopamine receptor blockade.
    Sedvall G; Bjerkenstedt L; Lindström L; Wode-Helgodt B
    Life Sci; 1978 Aug; 23(5):425-9. PubMed ID: 29184
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.